Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates
09:47am, Wednesday, 15'th Feb 2023
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen's stock gains after company beats Q4 revenue and earnings expectations
07:24am, Wednesday, 15'th Feb 2023
Shares of Biogen Inc. BIIB, -0.48% gained about 1.7% in premarket trading on Wednesday after the company beat revenue and earnings expectations in the fourth quarter. Biogen had earnings of $550.4 mil
2 Top Biotech Stocks Defying the Bear Market
02:00pm, Wednesday, 08'th Feb 2023
These stocks soared in the double digits last year.
Sage and Biogen's NDA for Depression Drug Gets Priority Review
03:17pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.
BIIB Stock: 1.64% Increase Explanation
02:24am, Tuesday, 07'th Feb 2023
The stock price of Biogen Inc (NASDAQ: BIIB) increased by 1.64% in the most recent trading session. This is why.
Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know
11:00pm, Monday, 06'th Feb 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'
05:14pm, Monday, 06'th Feb 2023 Benzinga
The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) zuranolone for major depressive disorder (MDD) a
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
11:30am, Monday, 06'th Feb 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the fili
Biogen: What To Do Ahead Of Q4 2022 Financial Report
07:12am, Monday, 06'th Feb 2023 Seeking Alpha
Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. Find out why BIIB stock is a Hold.
New Alzheimer's drug shows some promise, but has big price tag
10:39am, Thursday, 02'nd Feb 2023 MarketWatch
How to alleviate ravages of the disease without bankrupting individuals or Medicare program?
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
11:00pm, Monday, 30'th Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.
Lecanemab Receives Priority Review Status in Japan
11:30pm, Sunday, 29'th Jan 2023 GlobeNewswire Inc.
TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
02:57pm, Friday, 27'th Jan 2023 Zacks Investment Research
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
01:23pm, Friday, 27'th Jan 2023 Zacks Investment Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
11:30pm, Thursday, 26'th Jan 2023 GlobeNewswire Inc.
TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa
